NIBRT’s new world-class facilities on the UCD campus
The National Institute for Bioprocessing Research and Training (NIBRT) and GE Healthcare Life Sciences have announced a joint research collaboration to drive advances in technologies for the development of protein-based drugs that are increasingly used to treat diseases such as cancer, rheumatoid arthritis and multiple sclerosis. NIBRT and GE Healthcare are investing $0.5 million the first year in this project, which is planned to run for two years.
The goal of the collaboration is to develop new, robust and reproducible biochemical tests to replace current industry-standard techniques for research and manufacture, which are often labour intensive and highly variable. The collaboration will combine NIBRT’s leading expertise in in glycobiology and novel bioanalytical techniques with GE Healthcare’s capabilities in protein-protein interaction analysis, particularly the company’s Biacore™ SPR technology.
Welcoming the collaboration, Professor Ian Marison, NIBRT Interim Director said: “We are delighted with this research collaboration with GE Healthcare, which will allow NIBRT to apply its bioanalytical expertise to develop novel analytical platforms for the determination of monoclonal antibody biological activity. We look forward to working with GE Healthcare on this exciting project and developing our relationship further over time”.
The research will be led by NIBRT’s Principal Investigator and global leader in glycobiology, Professor Pauline Rudd, in conjunction with researchers from GE Healthcare Life Sciences laboratories in Uppsala, Sweden.
The National Institute for Bioprocessing Research and Training (NIBRT) is a global centre of excellence for training and research in bioprocessing. NIBRT is located in a new, world class facility on the UCD campus, which is purpose built to closely replicate a modern bioprocessing plant. NIBRT offers a quality training and research experience not previously possible anywhere in the world.
